However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...

Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...

A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with oestrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of ...

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

Please provide your email address to receive an email when new articles are posted on . Supportive therapies are necessary to help ensure patients adhere to aromatase inhibitor treatment, according to ...

A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Please provide your email address to receive an email when new articles are posted on . Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among ...

EPIK-B5 study evaluated alpelisib plus fulvestrant vs placebo for efficacy and safety in patients with PIK3CA-m HR+, HER2− advanced breast cancer who had progressed on a CDK4/6 inhibitor and an ...

Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.